- Home
- ABEV vs ALNY Comparison
ABEV vs ALNY Comparison
Compare ABEV & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEV
- ALNY
- Stock Information
- Founded
- ABEV 1885
- ALNY 2002
- Country
- ABEV Brazil
- ALNY United States
- Employees
- ABEV N/A
- ALNY N/A
- Industry
- ABEV Beverages (Production/Distribution)
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- ABEV Consumer Staples
- ALNY Health Care
- Exchange
- ABEV Nasdaq
- ALNY Nasdaq
- Market Cap
- ABEV 36.2B
- ALNY 33.1B
- IPO Year
- ABEV N/A
- ALNY 2004
- Fundamental
- Price
- ABEV $2.06
- ALNY $245.44
- Analyst Decision
- ABEV Hold
- ALNY Buy
- Analyst Count
- ABEV 1
- ALNY 23
- Target Price
- ABEV $2.50
- ALNY $298.59
- AVG Volume (30 Days)
- ABEV 30.4M
- ALNY 671.5K
- Earning Date
- ABEV 10-31-2024
- ALNY 02-13-2025
- Dividend Yield
- ABEV N/A
- ALNY N/A
- EPS Growth
- ABEV N/A
- ALNY N/A
- EPS
- ABEV 0.16
- ALNY N/A
- Revenue
- ABEV $15,133,784,839.00
- ALNY $2,094,795,000.00
- Revenue This Year
- ABEV $11.37
- ALNY $25.14
- Revenue Next Year
- ABEV $5.64
- ALNY $17.35
- P/E Ratio
- ABEV $12.34
- ALNY N/A
- Revenue Growth
- ABEV N/A
- ALNY 21.54
- 52 Week Low
- ABEV $2.01
- ALNY $141.98
- 52 Week High
- ABEV $2.85
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- ABEV 38.74
- ALNY 43.56
- Support Level
- ABEV $2.01
- ALNY $233.41
- Resistance Level
- ABEV $2.34
- ALNY $249.58
- Average True Range (ATR)
- ABEV 0.07
- ALNY 7.63
- MACD
- ABEV -0.02
- ALNY -0.21
- Stochastic Oscillator
- ABEV 11.84
- ALNY 48.68
About ABEV Ambev S.A.
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving Interbrew (now AB InBev) a controlling interest of 61.8% as at the end of 2023.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.